Dr Reddy's Laboratories (DRL) announced the launch of Ziprasidone Hydrochloride capsules, a bioequivalent generic version of Pfizer's `Geodon', in the US market, following the approval by the United States Food and Drug Administration ( USFDA) of DRL's ANDA for the capsules.
The `Geodon' brand had US sales of approximately $1.34 billion for the twelve months ended December 2011, according to IMS Health.
DRL's Ziprasidone Hydrochloride capsules in 20 mg, 40 mg, 60 mg and 80 mg strengths are available in 60 count bottle size.
Hyderabad-based DRL said it launched the generic version of Geodon capsules in the US market, used in treating mental disorders, on 2 March.
DRL had reported after-tax profit of Rs520 crore for the quarter ended 31 December 2012 – a 91% year-on-year increase from the similar quarter of the previous year.
Revenues for Q3 of FY12 stood at Rs2,770 crore, up 46% from revenues in the corresponding quarter of the previous year. Revenues for the first nine months of the financial year rose 29% to Rs7,020 crore.
DRL's generic revenues from North America stood at Rs1,110 crore in Q3 FY12 against Rs480 crore in Q3 of FY11. The growth was led by the high value launch of olanzapine 20 mg, new products launched in the last twelve months and strong volume growth across key products, DRL said.
....more info
The `Geodon' brand had US sales of approximately $1.34 billion for the twelve months ended December 2011, according to IMS Health.
DRL's Ziprasidone Hydrochloride capsules in 20 mg, 40 mg, 60 mg and 80 mg strengths are available in 60 count bottle size.
Hyderabad-based DRL said it launched the generic version of Geodon capsules in the US market, used in treating mental disorders, on 2 March.
DRL had reported after-tax profit of Rs520 crore for the quarter ended 31 December 2012 – a 91% year-on-year increase from the similar quarter of the previous year.
Revenues for Q3 of FY12 stood at Rs2,770 crore, up 46% from revenues in the corresponding quarter of the previous year. Revenues for the first nine months of the financial year rose 29% to Rs7,020 crore.
DRL's generic revenues from North America stood at Rs1,110 crore in Q3 FY12 against Rs480 crore in Q3 of FY11. The growth was led by the high value launch of olanzapine 20 mg, new products launched in the last twelve months and strong volume growth across key products, DRL said.
....more info